Initial experience with CytoSorb therapy in patients receiving left ventricular assist devices.
Konstantin ZhigalovJef Van den EyndeAlina ZubarevichThomas ChroschLukas GoerdtArian Arjomandi RadRobert VardanyanMichel Pompeu Barros Oliveira SáPeter LuedikeNikolaus PizanisAchim KochBastian SchmackMarkus KamlerArjang RuhparwarAlexander WeymannPublished in: Artificial organs (2021)
Overall, our results showed that CytoSorb might not convey a significant morbidity or mortality benefit for patients undergoing LVAD implantation.
Keyphrases
- patients undergoing
- left ventricular
- cardiovascular events
- heart failure
- acute myocardial infarction
- hypertrophic cardiomyopathy
- cardiac resynchronization therapy
- aortic stenosis
- type diabetes
- stem cells
- left atrial
- cardiovascular disease
- atrial fibrillation
- acute coronary syndrome
- ejection fraction
- replacement therapy